Elsevier

Vaccine

Volume 34, Issue 4, 20 January 2016, Pages 451-457
Vaccine

Alterations in serotype-specific B cell responses to the 13-valent pneumococcal conjugate vaccine in aging HIV-infected adults

https://doi.org/10.1016/j.vaccine.2015.12.013Get rights and content

Abstract

Background

Advanced age and human immunodeficiency virus (HIV) infection are associated with increased pneumococcal disease risk. The impact of these factors on cellular responses to vaccination is unknown.

Methods

HIV-infected (HIV+) individuals 50–65 years old with CD4+ T cells/μl (CD4) >200 on antiretroviral therapy (ART) ≥1 year received either the 13-valent pneumococcal conjugate vaccine followed by the 23-valent pneumococcal polysaccharide vaccine (PCV/PPV) or PPV only. HIV-uninfected (HIV−) controls received PCV/PPV. Phenotype distribution and surface expression of complement receptor CD21 and tumor necrosis factor superfamily receptors (TNFRs) were compared on serotype-specific B cells postvaccination.

Results

Postvaccination serotype-specific B cell percentages were significantly lower in HIV+ PCV/PPV compared to PPV groups, but similar between HIV+ or HIV− PCV/PPV groups. Transmembrane activator and calcium-modulating cyclophilin ligand interactor (TACI)+ serotype-specific B cell percentages were significantly decreased in HIV+ PCV/PPV compared to PPV groups. CD21+ serotype-specific B cells were significantly higher in HIV− compared to HIV+ PCV/PPV groups.

Conclusions

An initial dose of PCV reduced the frequency, but not phenotype distribution, of serotype-specific B cells and also lowered TACI expression in aging HIV+ subjects postvaccination with PPV. These findings suggest that PCV does not enhance cellular responses to revaccination with PPV.

Introduction

The success of ART has led to a substantial increase in life expectancy for HIV+ individuals [1]. Approximately one-half of HIV+ individuals living in the United States are estimated to be ≥50 years old [2]. Aging and HIV infection both result in profound immunological changes due to chronic antigenic stress [2], [3], [4], [5]. Similarities and differences, as well as the synergism, between these processes remain poorly understood.

PPV immunization generates impaired antibody responses in both elderly and HIV+ individuals, and effectiveness in preventing pneumococcal disease is controversial [6], [7], [8], [9]. The Advisory Committee on Immunization Practices (ACIP) currently recommends that HIV+ adults receive a single dose of PCV followed by a dose of PPV 8 weeks later (PCV/PPV) [10]. Superiority of PCV, however, is also questionable, as immunogenicity studies comparing single doses or combined regimens of PCV and PPV have yielded variable results [11], [12], [13], [14], [15], [16].

Further investigation into the underlying cellular mechanisms responsible for pneumococcal vaccine responses is urgently needed. In humans, evidence suggests that both IgM and switched memory B cells generate antibodies to pneumococcal antigens [17]. Several studies have reported an association between reduced memory B cell subsets and impaired responses to vaccination in elderly and HIV+ individuals [18], [19], [20], [21]. However, these analyses were performed on total rather than antigen-specific B cell populations.

We have previously characterized the phenotype of B cells responding to PPV in young adults, elderly, and HIV+ [22], [23], [24], [25]. The majority of serotype-specific B cells are IgM memory B cells in young, immunocompetent adults [22], [23]. Both elderly and HIV+ adults exhibit significant reductions in this subset that may contribute to decreased vaccine responsiveness [23], [24], [25]. However, unlike the elderly, HIV+ adults lack an increase in the proportion of serotype-specific switched memory B cells. Our data suggest that elderly and HIV+ individuals exhibit distinct perturbations in B cell subsets critical for protection against pneumococcal disease.

Older HIV+ individuals may possess a unique cellular response to vaccination reflecting the combined effects of aging and HIV infection. In the present study, we assessed the phenotype of B cells responding to the recommended PCV/PPV regimen compared to a single dose of PPV in HIV+ adults aged 50–65 years. We also sought to identify differences in surface expression of B cell receptors, including complement receptor CD21 and TNFRs CD40, TACI, and B cell-activating factor receptor (BAFF-R), on serotype-specific B cells that may contribute to vaccine responses.

Section snippets

Study design

Volunteers 50–65 years old were recruited between April 2012 and January 2015 in this University of Toledo Institutional Review Board-approved study. Written, informed consent was obtained from all subjects. Exclusion criteria included: active infection (except HIV), PPV <5 years prior, pregnancy, immunosuppressive medications, and prior history of splenectomy or other immunocompromising conditions as defined by ACIP vaccination recommendations [10]. Volunteers were questioned about any past

Subjects

Baseline characteristics are reported in Table 1. Differences in the distribution of sex and race in HIV− compared to HIV+ subjects were noted. Clinical characteristics, including CD4 count at enrollment and use of ART, were similar between HIV+ groups. A larger proportion of HIV+ participants had been immunized with PPV ≥5 years prior (85%) compared to HIV− (7%). Quantitative and qualitative antibody responses to pneumococcal vaccination were assessed in a separate study (submitted

Discussion

In the current study, we assessed B cells responding to the recommended PCV/PPV regimen compared to a single dose of PPV in HIV+ adults 50–65 years old. We identified serotype-specific B cells using fluorescently-labeled PPS as previously described by our laboratory [22], [23], [24], [25]. Serotype-specific B cell percentages post-PPV were significantly lower in the HIV+ PCV/PPV group compared to the HIV+ PPV group, suggesting that an initial dose of PCV limits the frequency of responding B

Funding

This work was supported by National Institutes of Health [RO1A081558 and RO1AG045973 to M.A.J.W.].

Acknowledgements

We thank all study volunteers for their participation and the Division of Infectious Diseases physicians and staff at the University of Toledo Medical Center in Toledo, Ohio for their assistance with recruitment.

Conflict of interest: All authors have no potential conflicts of interest.

References (44)

  • H. Samji et al.

    Closing the gap: increases in life expectancy among treated HIV-positive individuals in the United States and Canada

    PLOS ONE

    (2013)
  • R.B. Effros et al.

    Aging and infectious diseases: workshop on HIV infection and aging: what is known and future research directions

    Clin Infect Dis: Off Publ Infect Dis Soc Am

    (2008)
  • K.P. High et al.

    HIV and aging: state of knowledge and areas of critical need for research. A report to the NIH Office of AIDS Research by the HIV and Aging Working Group

    J Acquir Immune Defic Syndr

    (2012)
  • S.G. Deeks

    HIV infection, inflammation, immunosenescence, and aging

    Annu Rev Med

    (2011)
  • R.H. Pedersen et al.

    The effectiveness of pneumococcal polysaccharide vaccination in HIV-infected adults: a systematic review

    HIV Med

    (2011)
  • M.S. Dworkin et al.

    Pneumococcal disease among human immunodeficiency virus-infected persons: incidence, risk factors, and impact of vaccination

    Clin Infect Dis: Off Publ Infect Dis Soc Am

    (2001)
  • S. Moberley et al.

    Vaccines for preventing pneumococcal infection in adults

    Cochrane Database Syst Rev

    (2013)
  • A. Huss et al.

    Efficacy of pneumococcal vaccination in adults: a meta-analysis

    CMAJ: Can Med Assoc J [J Assoc Med Can]

    (2009)
  • Centers for Disease C Prevention

    Use of 13-valent pneumococcal conjugate vaccine and 23-valent pneumococcal polysaccharide vaccine for adults with immunocompromising conditions: recommendations of the Advisory Committee on Immunization Practices (ACIP)

    MMWR Morb Mortal Wkly Rep

    (2012)
  • N.F. Crum-Cianflone et al.

    A randomized clinical trial comparing revaccination with pneumococcal conjugate vaccine to polysaccharide vaccine among HIV-infected adults

    J Infect Dis

    (2010)
  • P. Lesprit et al.

    Immunological efficacy of a prime-boost pneumococcal vaccination in HIV-infected adults

    AIDS

    (2007)
  • M. Penaranda et al.

    Conjugate and polysaccharide pneumococcal vaccines do not improve initial response of the polysaccharide vaccine in HIV-infected adults

    AIDS

    (2010)
  • Cited by (0)

    1

    These authors contributed equally to this work.

    View full text